Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SHANGHAI PECHEM
00338
5
SINOPEC CORP
00386
No Data
Analyst Maintains Hold on ResMed as Noctrix Acquisition Offers Limited Incremental Growth Amid Competitive Risks
Macquarie Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
Health Care Roundup: Market Talk
Australia R&D Changes Look Positive for CSL, Others -- Market Talk
ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan
Express News | Resmed Inc-4 Statement of Changes in Beneficial Ownership